The clinical presentation of Guillain–Barré syndrome (GBS) is heterogeneous and, despite effective treatments, some patients die or sustain severe disabilities. An improved clinical prognostic ...

The primary endpoint, GBS-Disability Scale (DS), showed that after a single infusion of tanruprubart at 30 mg/kg dose, patients had a statistically significant 2.4-fold higher likelihood of being ...

The GBS-DS is a 7-point scale, but at the request of the FDA, Allen said, it was collapsed into a 3-point scale for this analysis. Scores of 0 and 1 indicated a good state of health, ...

The Phase 3 trial met its primary endpoint, with ANX005 30 mg/kg achieving a highly statistically significant 2.4-fold improvement on the GBS-disability scale (GBS-DS) at week 8 (proportional odds ...

Patients treated with tanruprubart were approximately three times more likely to be in a better state of health than patients on IVIg or PE on the GBS-Disability Scale (GBS-DS) at Weeks 4, 8, and 26 ...

MONTREAL — An investigational targeted immunotherapy for Guillain-Barré syndrome (GBS) more than doubled improvement in disability after 8 weeks compared with placebo and showed sustained ...

GBS begins with tingling or numbness in the feet and hands, ... What is not clear is whether this has been due to large scale contamination of water supply or a lot of people consuming infected ...

The primary endpoint, GBS-Disability Scale (DS), showed that after a single infusion of tanruprubart at 30 mg/kg dose, patients had a statistically significant 2.4-fold higher likelihood of being ...